A1M Pharma AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
30
About the Report
About the Report
Summary
A1M Pharma AB (A1M Pharma) is a developer of a medical application for the diagnosis and treatment of pre-eclampsia and acute renal damage. The company develops and commercializes drug candidate for the diagnosis and treatment of pre-eclampsia (pandemic poisoning) and acute renal injury. It offers products such as ROSgard based on A1M (alpha-1-microglobulin), an endogenous protein with properties that captures and eliminates toxic substances from the cells metabolism. A1M Pharma's A1M helps to prevent and ameliorate some of the damage caused by oxidative stress and inflammation; and develops novel diagnostic test for preeclampsia based on the biomarker fetal hemoglobin. The company also develops treatments for kidney damage. It also provides constitute therapeutic or diagnostic tools for various conditions and illnesses in animals and humans. A1M Pharma is headquartered in Lund, Sweden.
A1M Pharma AB-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
A1M Pharma AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
A1M Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
A1M Pharma AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
A1M Pharma Partnered with Clinical Trial Consultants 11
A1M Pharma Enters into Agreement with Research Toxicology Centre 12
A1M Pharma Enters into Research Agreement with CSL Behring 13
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 14
A1M Pharma Expands Agreement with European Pharmaceutical Company 15
A1M Pharma Enters into Partnership with Truly Translational 16
NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 17
Equity Offering 18
A1M Pharma Plans to Raise USD10.5 Million in Rights Offering of Shares 18
A1M Pharma Plans to Raise USD13.82 Million in Public Offering of Shares 19
A1M Pharma Raises USD5 Million in Rights Offering of Shares 20
A1M Pharma Raises USD3.7 Million in Rights Offering of Shares 21
A1M Pharma Raises USD3.61 Million in Rights Offering of Shares 22
A1M Pharma AB-Key Competitors 23
A1M Pharma AB-Key Employees 24
A1M Pharma AB-Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Corporate Communications 26
Aug 14, 2018: A1M Pharma names Tobias Larsson Agervald as Chief Medical Officer 26
Product News 27
02/10/2017: A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studies 27
Clinical Trials 28
Jun 12, 2017: A1M Pharma announces progress in the preclinical development of ROSGard 28
Mar 29, 2017: A1M Pharma: ROSGard shows strong protective effect against renal damage in connection with radiation therapy in a preclinical long-term study 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30
List of Figure
List of Figures
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9
List of Table
List of Tables
A1M Pharma AB, Pharmaceuticals & Healthcare, Key Facts 2
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
A1M Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
A1M Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 8
A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9
A1M Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
A1M Pharma Partnered with Clinical Trial Consultants 11
A1M Pharma Enters into Agreement with Research Toxicology Centre 12
A1M Pharma Enters into Research Agreement with CSL Behring 13
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 14
A1M Pharma Expands Agreement with European Pharmaceutical Company 15
A1M Pharma Enters into Partnership with Truly Translational 16
NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 17
A1M Pharma Plans to Raise USD10.5 Million in Rights Offering of Shares 18
A1M Pharma Plans to Raise USD13.82 Million in Public Offering of Shares 19
A1M Pharma Raises USD5 Million in Rights Offering of Shares 20
A1M Pharma Raises USD3.7 Million in Rights Offering of Shares 21
A1M Pharma Raises USD3.61 Million in Rights Offering of Shares 22
A1M Pharma AB, Key Competitors 23
A1M Pharma AB, Key Employees 24
A1M Pharma AB, Subsidiaries 25
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.